Fujian Haixi Pharmaceuticals

NeuExcell Therapeutics is an early-stage gene therapy company dedicated to addressing neurodegenerative diseases and neural injuries. The company has developed an innovative neural repair technology that facilitates the conversion of astrocytes into neurons through in vivo methods. By employing adeno-associated virus-based gene therapy to introduce neural transcription factors, NeuExcell aims to enable clinicians to restore damaged neural tissue. The company's mission is to enhance the quality of life for millions of patients worldwide who are affected by neurodegenerative conditions.